Enzyme-responsive vitamin D-based micelles for paclitaxel-controlled delivery and synergistic pancreatic cancer therapy
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most feared diseases worldwide owing to its poor prognosis, negligible therapeutic advances, and high mortality. Herein, multifunctional enzyme-responsive micelles for the controlled delivery of paclitaxel (PTX) were prepared to circumvent i...
Saved in:
Main Authors: | Diana Peixoto, João M. Ravasco, Barbara Blanco-Fernandez, Francisco Veiga, Angel Concheiro, João Conde, Ana Cláudia Paiva-Santos, Carmen Alvarez-Lorenzo |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2025-04-01
|
Series: | Materials Today Bio |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425001139 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
1.4 nm gold nanoparticle-antibody conjugates for in situ gold immunolabelling after transduction into living human cells
by: Groysbeck, Nadja, et al.
Published: (2023-10-01) -
Prognostic significance of ımmunhistochemical axl expression in pancreas ductal adenocarcinomas
by: Ozden Oz, et al.
Published: (2023-07-01) -
Multiphoton imaging-based quantifiable collagen signatures for predicting outcomes in patients with pancreatic ductal adenocarcinoma
by: Xiwen Chen, et al.
Published: (2025-02-01) -
Most oncological pancreas resections must consider the mesopancreas
by: S. A. Safi, et al.
Published: (2025-02-01) -
Phase II trial of nab-paclitaxel plus ramucirumab in combination with nivolumab for unresectable advanced or recurrent gastric cancer after progression on first-line treatment including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody (PADDLE)
by: Hidekazu Hirano, et al.
Published: (2025-02-01)